TELA Bio, Inc. (NASDAQ:TELA) reported mixed results for the fourth quarter on Tuesday.
The company posted quarterly losses of 17 cents per share which beat the analyst consensus estimate of losses of 18 cents per share. The company reported quarterly sales of $20.869 million which missed the analyst consensus estimate of $21.047 million.
TELA Bio said it sees first-quarter sales of $18.500 million versus market estimates of $21.277 million.
“We closed 2025 with our strongest quarterly revenue on record, delivering $20.9 million and 18% growth over Q4 2024 while holding operating expenses essentially flat for the year, demonstrating the operating leverage we expect to continue to see in the years ahead,” said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. “Over the last six months we strengthened our leadership and upgraded the commercial field organization. Today, the team we have assembled is the best we have ever had, with 89 revenue-generating reps in place to drive greater penetration into key markets throughout the U.S. Based on the current ramp of tenured reps in the field, we are confident in the team’s ability to deliver at least 8% revenue growth in 2026, and keep us on a path to profitability without the need to raise additional capital.”
TELA Bio shares dipped 9.4% to close at $0.6901 on Wednesday.
These analysts made changes to their price targets on TELA Bio following earnings announcement.
- Canaccord Genuity analyst Caitlin Roberts maintained TELA Bio with a Buy and lowered the price target from $4 to $2.
- Lake Street analyst Frank Takkinen maintained TELA Bio with a Buy and lowered the price target from $3 to $2.
- Piper Sandler analyst Matt O’Brien maintained the stock with a Neutral and lowered the price target from $1.25 to $1.
Considering buying TELA stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments